Results per Page:
Nextstrain virus-tracking platform moves into new phase
Dr. JT McCrone will oversee Gates Foundation-funded efforts to further empower users
COVID variant success involves more than viral load
Hyrien Lab, Vaccine and Infectious Disease Division
Beyond neutralization: the secret life of ADCC antibodies
From the Overbaugh Lab, Human Biology Division
Double trouble: two forms of antigenic stimulation confer protection against COVID-19
From Dr. Aaron Hudson and colleagues, Vaccine and Infectious Disease Division
A COVID-19 Antiviral, Reconsidered: What modeling reveals about Molnupiravir
From the Schiffer Lab, Vaccine and Infectious Disease Division
A moving target: How spike’s shape determines immune escape in SARS-CoV-2
From the Bloom Lab, Basic Sciences Division
Data-driven enrollment for COVID-19 vaccine clinical trials
From the HIV Vaccine Trials Network/COVID-19 Prevention Network
RR tracks: a new way to measure viral transmission
From the Bedford Lab, Vaccine and Infectious Disease, Public Health and Human Biology Divisions
Managing mountains of genomic data
Tools invented at Fred Hutch are helping researchers analyze the enormous global database of genomic sequences of the virus that causes COVID-19 to better understand how pathogens evolve and spread
Natural born killers: harnessing innate immunity to fight severe infections
From the Joshua Hill lab, Vaccine and Infectious Disease Division
COVID watchdawgs: SARS-CoV-2 at UW in the pandemic’s early days
From the Chu and Weil Labs, UW Medicine, in collaboration with the Cancer Basic Biology Program of the Cancer Consortium and Fred Hutch Vaccine and Infectious Disease Division
Identificación de anticuerpos potentes y ampliamente neutralizantes contra los sarbecovirus, incluidos el SARS-CoV-1 y el SARS-CoV-2
Del Laboratorio Overbaugh, División de Biología Humana
Drs. Keith Jerome and Jesse Bloom elected fellows of American Academy of Microbiology
Fred Hutch researchers’ study of viruses evolves from basic understanding to practical applications
With respiratory infections rampant, experts urge masking and vaccination
Limited disease data makes it hard to accurately assess flu trends
Identification of potent and broadly-neutralizing antibodies against sarbecoviruses including SARS-CoV-1 and SARS-CoV-2
From the Overbaugh lab, Human Biology Division
Crunching the numbers for next-gen COVID-19 vaccines
BARDA taps Fred Hutch biostatisticians to assess new vaccine technology, more nimble trial design
¿Necesito otra vacuna de refuerzo contra el SRAS-CoV-2?
Del Dr. Bo Zhang y laboratorios colaboradores, División de Vacunas y Enfermedades Infecciosas